List of Excipients in Branded Drug CINVANTI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Heron Therapeutics Inc	CINVANTI	aprepitant	47426-201	ALCOHOL
Heron Therapeutics Inc	CINVANTI	aprepitant	47426-201	EGG PHOSPHOLIPIDS
Heron Therapeutics Inc	CINVANTI	aprepitant	47426-201	SODIUM OLEATE
Heron Therapeutics Inc	CINVANTI	aprepitant	47426-201	SOYBEAN OIL
Heron Therapeutics Inc	CINVANTI	aprepitant	47426-201	SUCROSE
Heron Therapeutics Inc	CINVANTI	aprepitant	47426-201	WATER

CINVANTI Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: August 19, 2026

CINVANTI is an intravenous aprepitant injectable emulsion developed to avoid the polysorbate 80 and dehydrated alcohol excipients used in the original EMEND IV formulation. Its commercial value rests on a technically differentiated lipid-emulsion platform, a complex abbreviated approval pathway for competing generics, and patent protection directed to the formulation rather than the aprepitant molecule alone.

What is CINVANTI and which excipients does it contain?

CINVANTI is an intravenous injectable emulsion containing aprepitant, a neurokinin-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting. The product is supplied as a 130 mg/18 mL single-dose vial and is administered by intravenous infusion after dilution in a compatible solution. The FDA approved CINVANTI in November 2017 under NDA 210660. [1]

The FDA-approved inactive ingredients are:

Excipient	Functional role
Soybean oil	Dispersed oil phase and solvent for the lipophilic drug
Egg lecithin	Emulsifier and interfacial stabilizer
Sodium oleate	Co-emulsifier and surface-charge modifier
Sucrose	Tonicity adjustment and stabilization
Water for injection	Continuous aqueous phase

CINVANTI does not use polysorbate 80 or dehydrated alcohol. Those excipients are associated with the original intravenous fosaprepitant and aprepitant products, including concerns involving hypersensitivity, infusion-site reactions and compatibility. The CINVANTI label identifies soybean oil and egg lecithin, which create relevant contraindication and allergy-screening considerations. [1]

How does CINVANTI compare with EMEND IV?

Attribute	CINVANTI	EMEND IV
Active ingredient	Aprepitant	Fosaprepitant dimeglumine
Delivery system	Lipid injectable emulsion	Aqueous solution after reconstitution/dilution
Key formulation excipients	Soybean oil, egg lecithin, sodium oleate, sucrose	Polysorbate 80, disodium edetate and other excipients
Alcohol content	No dehydrated alcohol	Formulation historically used dehydrated alcohol in the IV product
Dose	130 mg aprepitant	150 mg fosaprepitant dimeglumine
Administration	IV infusion	IV infusion
Primary commercial distinction	Excipient and tolerability positioning	Established fosaprepitant brand and generic competition

CINVANTI's excipient strategy is commercially relevant because it changes the risk profile of the intravenous product while preserving the clinical role of aprepitant in highly emetogenic and moderately emetogenic chemotherapy regimens.

What formulation is protected by CINVANTI patents?

CINVANTI's principal intellectual-property position is associated with a formulation patent directed to injectable aprepitant emulsions. U.S. Patent No. 9,629,823, titled "Injectable formulations of aprepitant," is the central publicly identified patent associated with the product's formulation protection. [2]

Patent	Subject matter	Priority date	Patent expiration
U.S. 9,629,823	Injectable aprepitant formulation and related pharmaceutical compositions	June 12, 2014	June 12, 2035, before any applicable patent-term adjustment or extension

The patent is important because aprepitant itself is an older active ingredient. A competitor that copies the CINVANTI formulation may face a composition-of-matter or formulation patent issue even though the active pharmaceutical ingredient is no longer broadly protected.

The relevant technical value is concentrated in the combination of:

• Aprepitant dispersed in a lipid emulsion.
• Soybean oil as a lipophilic vehicle.
• Egg lecithin as an emulsifier.
• Sodium oleate as a stabilizing or co-emulsifying agent.
• Sucrose in the aqueous phase.
• Particle-size, pH, osmolality and physical-stability characteristics suitable for intravenous administration.

The patent estate is stronger against a direct formulation copy than against every possible aprepitant injectable. A generic sponsor may attempt to design around one or more excipients, alter the oil phase, substitute a synthetic phospholipid, use a different surfactant system or pursue a non-emulsion formulation.

How many patents cover CINVANTI and what is the Orange Book status?

The Orange Book should be treated as the controlling source for listed patents and regulatory exclusivity. FDA's product-specific listings identify the patent information associated with approved products and determine the relevant timing for ANDA certifications. [3]

CINVANTI's commercial exclusivity is primarily patent-based. The product's five-year new chemical entity exclusivity does not apply because aprepitant had previously been approved in the United States. The key business issue is therefore the scope and enforceability of formulation patents rather than loss of active-ingredient exclusivity.

A commercial diligence review should distinguish among:

1. Patents listed in the Orange Book.
2. Unlisted formulation, process or manufacturing patents.
3. Patent-term adjustment.
4. Pediatric exclusivity, if granted.
5. Regulatory exclusivity tied to the NDA.
6. Litigation outcomes and settlement restrictions.

The public record supports treating U.S. 9,629,823 as the principal formulation patent. A patent-count estimate that includes every continuation, foreign counterpart, manufacturing patent or unpublished application would not be reliable without a current patent-family search.

When does CINVANTI lose exclusivity?

CINVANTI's central U.S. formulation patent is scheduled to expire in June 2035, subject to any legally applicable patent-term adjustment or extension. The practical generic-entry date could occur earlier if:

• A generic applicant receives a favorable Paragraph IV litigation outcome.
• The patent is narrowed, invalidated or disclaimed.
• The patent holder settles on terms permitting an earlier launch.
• A competing product does not infringe the listed claims.
• FDA approves an alternative aprepitant injectable through a route that does not require certification to the listed patent.

The 2035 date should not be interpreted as a guaranteed market-protection date. The effective barrier depends on claim scope, the Orange Book listing, ANDA certifications and litigation.

What Paragraph IV challenges affect CINVANTI?

A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. A first applicant that submits a valid Paragraph IV certification may receive 180 days of generic exclusivity, subject to statutory forfeiture provisions and the specific ANDA history. [4]

Publicly identified CINVANTI patent disputes should be monitored through:

• FDA's Orange Book patent-listing data.
• FDA's Paragraph IV litigation database and ANDA records.
• PACER and federal district-court dockets.
• Patent Trial and Appeal Board proceedings.
• SEC filings by Heron Therapeutics and generic applicants.

The commercial risk is asymmetric. A direct-copy emulsion may be exposed to an infringement suit under U.S. 9,629,823. A materially different formulation may reduce infringement risk but increase development, analytical and clinical-bridging costs.

How strong is the CINVANTI patent estate?

CINVANTI has a focused rather than broad patent estate. Its strongest protection is the technical combination that gives the product its injectable-emulsion identity.

Strengths

• The active ingredient is incorporated into a distinct delivery system.
• The formulation addresses a known limitation of earlier intravenous aprepitant products.
• Lipid injectable emulsions require extensive characterization beyond simple tablet-equivalence testing.
• Formulation claims can create meaningful freedom-to-operate constraints even after active-ingredient patents expire.
• Manufacturing consistency, droplet-size distribution and storage stability may be difficult to reproduce.

Weaknesses

• A single principal formulation patent creates concentration risk.
• Many excipients are conventional pharmaceutical ingredients.
• A competitor may seek a different emulsion architecture.
• Patent validity may be challenged on obviousness, written description or enablement grounds.
• The product's clinical differentiation may not justify a large price premium if generic intravenous alternatives become available.

Patent strength is therefore best characterized as moderate to strong against an exact or near-exact formulation copy, but less certain against a technically distinct aprepitant injectable.

What manufacturing barriers protect CINVANTI?

The commercial barrier is not limited to the written patent claims. Injectable emulsions require control of:

• Oil-droplet size and distribution.
• Emulsion uniformity.
• Physical and chemical stability.
• Sterility and endotoxin levels.
• Container-closure integrity.
• Compatibility with infusion bags and administration sets.
• Extractables and leachables.
• Dilution stability.
• Terminal sterilization or aseptic-processing performance.

Manufacturing typically involves high-shear mixing or homogenization, controlled addition of the emulsifier system, sterile filtration where feasible and validated aseptic filling. The process must preserve emulsion integrity while controlling degradation of aprepitant and oxidation of the lipid phase.

These requirements create a higher development burden than an immediate-release oral aprepitant capsule. They also make manufacturing know-how and process controls commercially relevant even if a competitor avoids literal infringement of the principal patent.

What generic entry risks exist for CINVANTI?

Generic competition can emerge through three principal routes.

Direct formulation copy

A sponsor may use the same or substantially similar excipients and seek an ANDA. This route offers the clearest development path but carries the highest Paragraph IV and infringement risk.

Design-around injectable emulsion

A sponsor may replace soybean oil, egg lecithin or sodium oleate with alternative lipid, phospholipid or surfactant systems. This approach may reduce patent exposure but require more extensive formulation development and analytical justification.

Alternative aprepitant dosage form

A sponsor may develop a non-emulsion injectable, a different parenteral salt or another delivery system. The product could face a more demanding regulatory pathway and may not qualify for the same abbreviated route as a conventional ANDA.

The principal commercial risk is a delayed but technically credible generic launch after patent expiry or litigation settlement. An authorized generic, licensing arrangement or second-source supply agreement could reduce the net impact on CINVANTI pricing before full generic entry.

What regulatory pathway applies to CINVANTI generics?

A generic version of an injectable product may qualify for an ANDA if the proposed product meets FDA requirements for pharmaceutical equivalence, bioequivalence and sameness or acceptable differences under the applicable product-specific guidance. Complex injectable emulsions can require more extensive characterization than simple aqueous solutions. [4]

Relevant review issues include:

• Qualitative and quantitative composition.
• Globule-size distribution.
• Zeta potential or related interfacial properties.
• pH and osmolality.
• In-vitro release or dispersion behavior.
• Stability under dilution conditions.
• Sterility assurance.
• Container-closure compatibility.
• Comparative impurity and degradation profiles.

A formulation that differs materially from the reference product may face questions over whether an ANDA is appropriate. That creates a regulatory barrier that can delay entry even when the active ingredient is well established.

What commercial opportunities exist in the CINVANTI excipient strategy?

Excipient supply and dual sourcing

The product depends on pharmaceutical-grade soybean oil, egg lecithin and sodium oleate with controlled quality attributes. Suppliers that can provide validated, low-variability materials, reliable documentation and global regulatory support may capture value through qualified second-source relationships.

Alternative excipient systems

There is a potential design-around market for:

• Synthetic phospholipids.
• Medium-chain or other pharmaceutical oils.
• Non-animal emulsifiers.
• Reduced-allergen lipid systems.
• Oxidation-resistant oil phases.
• Surfactant systems compatible with intravenous use.

These alternatives must match or improve CINVANTI's safety, stability and manufacturability profile. Replacing egg lecithin or soybean oil may address allergen or supply concerns but could create new toxicology and regulatory requirements.

Contract development and manufacturing

CDMOs with sterile-emulsion capabilities can compete for:

• Generic aprepitant development.
• Regional licensing projects.
• Hospital and group-purchasing supply contracts.
• Lifecycle-management products.
• Alternative antiemetic combination products.

The highest-value capabilities are sterile filling, high-pressure homogenization, analytical characterization and validated scale-up.

Combination products and oncology supportive care

CINVANTI is used as part of multidrug antiemetic regimens. Commercial opportunities include fixed-dose or co-packaged regimens with a 5-HT3 antagonist, dexamethasone or other supportive-care agents, subject to regulatory and patent constraints. A combination product could improve regimen convenience but would require new clinical, formulation and intellectual-property work.

How does CINVANTI compare with competing antiemetics?

Product or class	Main active ingredient	Delivery	Commercial threat to CINVANTI
Generic aprepitant capsules	Aprepitant	Oral	Substitution where oral therapy is suitable
EMEND IV generics	Fosaprepitant	IV	Direct parenteral NK1 competition
Akynzeo	Netupitant/palonosetron	Oral or IV, depending on product	Combination-regimen convenience
Varubi	Rolapitant	Oral	Alternative NK1 therapy
CINVANTI	Aprepitant	IV lipid emulsion	Differentiated excipient and IV formulation profile

CINVANTI competes on administration, formulation tolerability, hospital workflow and supply reliability. It does not have an exclusive clinical mechanism because other NK1 antagonists address the same therapeutic pathway.

What is CINVANTI's revenue exposure?

Heron Therapeutics does not generally report CINVANTI revenue as a standalone line in the same level of detail as total company revenue. Product-level exposure must therefore be assessed through company filings, oncology-supportive-care sales disclosures, contract arrangements and market-share data rather than a single public revenue figure. [5]

Revenue sensitivity is driven by:

• Hospital adoption of intravenous aprepitant.
• Reimbursement and contracting.
• Availability of fosaprepitant generics.
• CINVANTI's price relative to competing NK1 antagonists.
• Formulary placement.
• Supply continuity.
• Patent litigation and launch timing.

The key downside event is an ANDA launch that combines regulatory approval with a non-infringing formulation. The key upside event is sustained differentiation in hospitals that value the absence of polysorbate 80 and dehydrated alcohol.

What licensing and partnership opportunities exist?

The most credible licensing opportunities are formulation and manufacturing partnerships rather than licenses to the aprepitant molecule itself. Potential structures include:

• Regional commercialization rights.
• Supply agreements for sterile emulsion.
• Generic development licenses after patent expiry.
• Co-development of alternative excipient systems.
• Authorized-generic arrangements.
• CDMO partnerships with milestone and royalty economics.

The value of a license depends on whether it includes rights to the formulation patent, manufacturing know-how, regulatory files, clinical data, trademarks and geographic territories. A supply-only agreement may generate manufacturing revenue but provide limited control over downstream pricing.

Key Takeaways

• CINVANTI is an intravenous aprepitant lipid emulsion containing soybean oil, egg lecithin, sodium oleate, sucrose and water for injection.
• Its principal product differentiation is the absence of polysorbate 80 and dehydrated alcohol used in earlier IV aprepitant products.
• U.S. Patent No. 9,629,823 is the principal publicly identified formulation patent, with a scheduled June 2035 expiration before any applicable adjustment.
• The formulation patent is strongest against direct copies and weaker against technically distinct injectable designs.
• Generic development is complicated by emulsion characterization, sterile manufacturing and potential ANDA eligibility issues.
• Excipient suppliers, sterile-emulsion CDMOs and alternative lipid-system developers have the clearest commercial opportunities.
• CINVANTI's revenue exposure depends on hospital contracting, competing fosaprepitant products, product-level pricing and the timing of generic entry.
• Current Orange Book listings, Paragraph IV certifications and federal litigation dockets determine the operative U.S. entry risk.

FAQs

Does CINVANTI contain polysorbate 80?

No. CINVANTI uses a soybean oil and egg-lecithin emulsion system rather than polysorbate 80.

Is CINVANTI an aprepitant or fosaprepitant product?

CINVANTI contains aprepitant. It is distinct from EMEND IV products containing fosaprepitant dimeglumine.

Can a generic company copy CINVANTI's excipients?

It can attempt to do so, but an identical or substantially similar formulation may face infringement claims under listed formulation patents and may require a Paragraph IV certification.

Are CINVANTI's excipients suitable for patients with egg or soy allergies?

The FDA label identifies egg lecithin and soybean oil as inactive ingredients. Allergy-related use decisions depend on the product label, patient history and clinical judgment. [1]

Does CINVANTI have biologic or biosimilar competition?

No. CINVANTI is a small-molecule drug product. Its relevant competitive risks arise from generic aprepitant, fosaprepitant and alternative NK1 antagonist products, not biosimilars.

References

1. U.S. Food and Drug Administration. (2024). CINVANTI (aprepitant) injectable emulsion prescribing information.
2. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,629,823: Injectable formulations of aprepitant.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Generic drug regulatory framework.
5. Heron Therapeutics, Inc. (2024). Annual report on Form 10-K.